| Detected | Trial | Change |
|---|---|---|
| 2026-08-07 | NCT06516926 SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or… |
critical overall status: Not Yet Recruiting → Terminated |
| 2026-08-07 | NCT06516926 SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or… |
critical Trial terminated: The adjustment of the sponsor's R\&D strategy. |
| 2026-08-07 | NCT06516926 SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or… |
Enrollment reduced: 240 -> 11 participants |
| 2026-08-07 | NCT06516926 SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or… |
date change Primary completion moved earlier: 2025-11 -> 2025-05-23 |
| 2026-08-07 | NCT06516926 SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or… |
date change Completion moved earlier: 2026-12 -> 2025-05-23 |
| 2026-08-04 | NCT07711184 A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer |
Recruitment opened |
| 2026-07-31 | NCT07196774 A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in… |
Enrollment closed, study ongoing |
| 2026-07-31 | NCT06837077 Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in… |
Trial completed |
| 2026-07-31 | NCT06837077 Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in… |
date change Primary completion pushed: 2025-06 -> 2025-11-01 |
| 2026-07-31 | NCT06837077 Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in… |
date change Completion pushed: 2025-07 -> 2025-11-01 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-12 | NCT07760831 A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis | Phase 1 | Not Yet Recruiting |
| 2026-08-05 | NCT07746726 Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus… | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06344091 | A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients | Local Analgesia Via Infiltration | Recruiting |
| Phase 3 | |||
| NCT04316364 | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable… | Non-Small-Cell Lung Cancer | Recruiting |
| NCT06123494 | SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction… | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Recruiting |
| NCT06569056 | A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection… | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | Recruiting |
| NCT07238283 | Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV… | First-line Treatment of Metastatic Pancreatic Cancer | Recruiting |
| NCT06122389 | SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | Recruiting |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With… | Gastric Cancer | Recruiting |
| NCT06430437 | A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic… | Non-Small Cell Lung Cancer With HER2- Mutations | Recruiting |
| NCT07311694 | A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in… | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer | Recruiting |
| NCT06828354 | A Study of SHR-A1811 in Subjects With Ovarian Cancer | Ovarian Cancer | Recruiting |
| NCT07241416 | A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive… | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Recruiting |
| NCT05884255 | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With… | Advanced Gastroenteropancreatic Neuroendocrine Tumor | Recruiting |
| NCT07286032 | A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in… | Patients With Chemotherapy-Induced Thrombocytopenia | Recruiting |
| NCT07232875 | HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line… | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting | Recruiting |
| NCT04842617 | Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant… | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer | Active, Not Recruiting |
| NCT04961710 | Extension Study of Hetrombopag in Severe Aplastic Anemia | Treatment-naive Severe Aplastic Anemia | Active, Not Recruiting |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of… | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, Not Recruiting |
| NCT05864014 | Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With… | Chemotherapy-Induced Thrombocytopenia | Active, Not Recruiting |
| NCT06649773 | The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients | Type 2 Diabetes | Active, Not Recruiting |
| NCT05424835 | A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive… | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | Active, Not Recruiting |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic… | Cervical Cancer | Active, Not Recruiting |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With… | Hepatocellular Carcinoma | Active, Not Recruiting |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in… | Hepatocellular Carcinoma (HCC) | Active, Not Recruiting |
| NCT06057610 | A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive… | HER2-PositiveRecurrent or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT06126640 | A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in… | HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | Active, Not Recruiting |